|
INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR POSFREA™
INDICATIONS
Chemotherapy-Induced Nausea and Vomiting in Adults
POSFREA is indicated for:
- Moderately emetogenic cancer chemotherapy -- prevention of acute and delayed nausea and vomiting associated with initial and repeat courses
- Highly emetogenic cancer chemotherapy -- prevention of acute nausea and vomiting associated with initial and repeat courses
Postoperative Nausea and Vomiting in Adults
POSFREA is indicated for prevention of postoperative nausea and vomiting (PONV) for up to 24
hours following surgery. Efficacy beyond 24 hours has not been demonstrated.
As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is
little expectation that nausea and/or vomiting will occur postoperatively. In patients where
nausea and vomiting must be avoided during the postoperative period, POSFREA is
recommended even where the incidence of postoperative nausea and/or vomiting is low.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATION
POSFREA is contraindicated in patients known to have hypersensitivity to the drug or any of its
components
WARNINGS AND PRECAUTIONS
Hypersensitivity
Hypersensitivity reactions, including anaphylaxis, have been reported with or without known
hypersensitivity to other 5-HT3 receptor antagonists.
Serotonin Syndrome
The development of serotonin syndrome has been reported with 5-HT3 receptor antagonists. Most
reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin
reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine
oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue).
Some of the reported cases were fatal. Serotonin syndrome occurring with overdose of another 5-
HT3 receptor antagonist alone has also been reported. The majority of reports of serotonin
syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia care unit or an
infusion center.
Symptoms associated with serotonin syndrome may include the following combination of signs
and symptoms: mental status changes (e.g. agitation, hallucinations, delirium, and coma),
autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing,
hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia,
incoordination), seizures, with or without gastrointestinal symptoms (e.g., nausea, vomiting,
diarrhea). Patients should be monitored for the emergence of serotonin syndrome, especially with
concomitant use of POSFREA and other serotonergic drugs. If symptoms of serotonin syndrome
occur, discontinue POSFREA and initiate supportive treatment. Patients should be informed of the
increased risk of serotonin syndrome, especially if POSFREA is used concomitantly with other
serotonergic drugs.
ADVERSE REACTIONS
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates
observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials
of another drug and may not reflect the rates observed in practice.
The safety of POSFREA has been established from adequate and well-controlled studies of
another intravenous formulation of palonosetron HCl. Below is a display of the adverse reactions
of palonosetron HCl in these adequate and well-controlled studies.
Chemotherapy-Induced Nausea and Vomiting
In clinical trials for the prevention of nausea and vomiting induced by moderately or highly
emetogenic chemotherapy, 633 adult patients received a single 0.25 mg dose of palonosetron
HCl, 410 patients received a single 32 mg dose of ondansetron and 194 patients received a single
100 mg dose of dolasetron. Adverse reactions were similar in frequency and severity with
intravenous palonosetron HCl, ondansetron or dolasetron. The following adverse reactions were
reported by ≥ 2% of patients in these trials who received palonosetron HCL 0.25 mg
intravenously, ondansetron 32 mg intravenously, or dolasetron 100 mg intravenously,
respectively: headache (9%, 8%, 16%, respectively), constipation (5%, 2%, 6%, respectively),
diarrhea (1%, 2%, 2%, respectively), dizziness (1%, 2%, 2%, respectively), fatigue (<1%, 1%,
2%, respectively), abdominal pain (<1%, <1%, 2%, respectively), insomnia (<1%, 1%, 2%,
respectively).
In other studies, 2 subjects experienced severe constipation following a single palonosetron HCl
dose of approximately 0.75 mg, three times the recommended dose.
In clinical trials, the following infrequently reported adverse reactions, assessed by investigators
as treatment-related or causality unknown, occurred following administration of palonosetron
HCl to adult patients receiving concomitant cancer chemotherapy:
Cardiovascular: 1%: non-sustained tachycardia, bradycardia, hypotension, < 1%: hypertension,
myocardial ischemia, extrasystoles, sinus tachycardia, sinus arrhythmia, supraventricular
extrasystoles and QT prolongation. In many cases, the relationship to palonosetron was unclear.
Dermatological: < 1%: allergic dermatitis, rash.
Hearing and Vision: < 1%: motion sickness, tinnitus, eye irritation and amblyopia.
Gastrointestinal System: 1%: diarrhea, < 1%: dyspepsia, abdominal pain, dry mouth, hiccups and
flatulence.
General: 1%: weakness, < 1%: fatigue, fever, hot flash, flu-like syndrome.
Liver: < 1%: transient, asymptomatic increases in AST and/or ALT and bilirubin. These changes
occurred predominantly in patients receiving highly emetogenic chemotherapy.
Metabolic: 1%: hyperkalemia, < 1%: electrolyte fluctuations, hyperglycemia, metabolic acidosis,
glycosuria, appetite decrease, anorexia.
Musculoskeletal: < 1%: arthralgia.
Nervous System: 1%: dizziness, < 1%: somnolence, insomnia, hypersomnia, paresthesia.
Psychiatric: 1%: anxiety, < 1%: euphoric mood.
Urinary System: < 1%: urinary retention.
Vascular: < 1%: vein discoloration, vein distention.
Postoperative Nausea and Vomiting
Adverse reactions occurred in adults receiving intravenous palonosetron HCl 0.075 mg
immediately before induction of anesthesia in three randomized placebo-controlled trials. Rates
of adverse reactions between palonosetron HCl and placebo groups were similar. Some events
are known to be associated with, or may be exacerbated by concomitant perioperative and
intraoperative medications administered in this surgical population. The following adverse
reactions were reported by ≥ 2% of patients in these trials who received palonosetron HCL 0.075
mg intravenously compared to placebo: electrocardiogram QT prolongation (5% vs. 3%),
bradycardia (4% vs. 4%), headache (3% vs 4%), and constipation (2% vs 3%).
In these clinical trials, the following infrequently reported adverse reactions, assessed by
investigators as treatment-related or causality unknown, occurred following administration of
palonosetron HCl to adult patients receiving concomitant perioperative and intraoperative
medications including those associated with anesthesia:
Cardiovascular: 1% electrocardiogram QTc prolongation, sinus bradycardia, tachycardia; <1%:
blood pressure decreased, hypotension, hypertension, arrhythmia, ventricular extrasystoles,
generalized edema; ECG T wave amplitude decreased, platelet count decreased. The frequency
of these adverse effects did not appear to be different from placebo.
Dermatological: 1%: pruritus.
Gastrointestinal System: 1%: flatulence, < 1%: dry mouth, upper abdominal pain, salivary
hypersecretion, dyspepsia, diarrhea, intestinal hypomotility, anorexia.
General: < 1%: chills.
Liver: 1%: increases in AST and/or ALT< 1%: hepatic enzyme increased
Metabolic: < 1%: hypokalemia, anorexia.
Nervous System: < 1%: dizziness.
Respiratory: < 1%: hypoventilation, laryngospasm.
Urinary System: 1%: urinary retention.
Postmarketing Experience
The following adverse reactions have been identified during post approval use of another
intravenous formulation of palonosetron HCl. Because these reactions are reported voluntarily
from a population of uncertain size, it is not always possible to reliably estimate their frequency
or establish a causal relationship to drug exposure.
Very rare cases (<1/10,000) of hypersensitivity reactions including anaphylaxis and anaphylactic
shock and injection site reactions (burning, induration, discomfort and pain) were reported from
postmarketing experience of palonosetron HCl 0.25 mg in the prevention of chemotherapyinduced
nausea and vomiting.
DRUG INTERACTIONS
Serotonergic Drugs
Serotonin syndrome (including altered mental status, autonomic instability, and neuromuscular
symptoms) has been described following the concomitant use of 5-HT3 receptor antagonists and
other serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs) and serotonin
and noradrenaline reuptake inhibitors (SNRIs). Monitor for the emergence of serotonin syndrome.
If symptoms occur, discontinue POSFREA and initiate supportive treatment.
USE IN SPECIFIC POPULATIONS
Pregnancy
Risk Summary
There are no available data on palonosetron HCl use in pregnant women to inform a drugassociated
risk. In animal reproduction studies, no effects on embryo-fetal development were
observed with the administration of oral palonosetron HCl to rats and rabbits during
organogenesis at doses up to 1894 and 3789 times the recommended human intravenous dose,
respectively [see Data below].
The estimated background risk of major birth defects and miscarriage for the indicated
population is unknown. In the U.S. general population, the estimated background risk of major
birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%,
respectively.
Data
Animal Data
In animal reproduction studies, no effects on embryo-fetal development were observed in
pregnant rats given oral palonosetron HCl at doses up to 60 mg/kg/day (1894 times the
recommended human intravenous dose based on body surface area) or pregnant rabbits given
oral doses up to 60 mg/kg/day (3789 times the recommended human intravenous dose based on
body surface area) during the period of organogenesis.
Lactation
Risk Summary
There are no data on the presence of palonosetron in human milk, the effects of palonosetron on
the breastfed infant, or the effects of palonosetron on milk production. The developmental and
health benefits of breastfeeding should be considered along with the mother's clinical need for
POSFREA and any potential adverse effects on the breastfed infant from palonosetron or from
the underlying maternal condition.
Pediatric Use
This product has not been approved for use in pediatric patients for prevention of chemotherapyinduced
nausea and vomiting.
The safety and effectiveness of POSFREA for prevention of postoperative nausea and vomiting
have not been established in pediatric patients.
Geriatric Use
Of the 1374 adult cancer patients in clinical studies of intravenously administered palonosetron
HCl for CINV, 316 (23%) were aged 65 years and over, while 71 (5%) were aged 75 years and
over. Of the 1520 adult patients in clinical studies of intravenously administered palonosetron
HCl for PONV, 73 (5%) were age 65 years older. No overall differences in safety or
effectiveness were observed between these subjects and the younger subjects, but greater
sensitivity in some older individuals cannot be ruled out. Population pharmacokinetics analysis
did not reveal any differences in palonosetron pharmacokinetics between cancer patients ≥ 65
years of age and younger patients. No dose adjustment or special monitoring are required for
geriatric patients.
No overall differences in safety were observed between older and younger subjects in these
studies, though the possibility of heightened sensitivity in some older individuals cannot be
excluded. No differences in efficacy were observed in geriatric patients for the CINV indication
and none are expected for geriatric PONV patients. However, palonosetron HCl efficacy in
geriatric patients has not been adequately evaluated.
OVERDOSAGE
There is no known antidote to palonosetron HCl. Overdose should be managed with supportive
care.
Dialysis studies have not been performed, however, due to the large volume of distribution,
dialysis is unlikely to be an effective treatment for palonosetron HCl overdose. A single
intravenous dose of palonosetron HCl at 30 mg/kg (947 and 474 times the human dose for rats
and mice, respectively, based on body surface area) was lethal to rats and mice. The major signs
of toxicity were convulsions, gasping, pallor, cyanosis and collapse.
|